Global Osteoarthritis Therapeutics Market: Trends, Analysis, and Forecast 2021-2030

Osteoarthritis Therapeutics Market

Osteoarthritis Therapeutics

PORTLAND, OR, UNITED STATES, March 29, 2023 / -- The Osteoarthritis therapeutics market refers to the industry that produces and offers treatments for osteoarthritis, a common form of arthritis that affects millions of people worldwide. Osteoarthritis is characterized by the breakdown of cartilage in the joints, leading to pain, stiffness, and loss of mobility.

The global osteoarthritis therapeutics market has been growing steadily in recent years, driven by factors such as an increase in the aging population, rising prevalence of osteoarthritis, and growing awareness about the condition. The global osteoarthritis therapeutics market size was valued at $6,754.1 million in 2020, and is estimated to reach $15,693.8 million by 2030, growing at a CAGR of 8.8% from 2021 to 2030.

Some of the key players in the osteoarthritis therapeutics market include Abbott Laboratories, Bayer AG, Flexion Therapeutics, Inc., and GlaxoSmithKline plc., Horizon Therapeutics plc., Johnson & Johnson, Novartis, Pfizer Inc., Sanofi, and Zimmer Biomet Holding. These companies offer a range of treatments for osteoarthritis, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and hyaluronic acid injections.

The osteoarthritis therapeutics market is highly regulated, and treatments must comply with strict safety and efficacy standards set by organizations such as the FDA and EMA. As a result, there is a growing demand for innovative and effective treatments that meet these requirements while also being affordable and accessible.

Overall, the osteoarthritis therapeutics market is expected to continue to grow in the coming years as the prevalence of osteoarthritis increases and technological advancements make treatments more effective and efficient. This presents both opportunities and challenges for providers, who must balance the need for innovation and safety with the need for profitability and growth.

๐‘๐ž๐ช๐ฎ๐ž๐ฌ๐ญ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐š๐ญ:

Surge in the prevalence of osteoarthritis, rise in the geriatric population, and the increase in R&D activities for developing new and better drugs propel the market growth. On the other hand, risk associated with the use of non-steroidal anti-inflammatory drugs and cost of drugs used to treat osteoarthritis hinder the market growth. On the contrary, changes in government policies and rise in healthcare expenses across the world create opportunities for the market players.

๐–๐ก๐š๐ญ ๐ข๐ฌ ๐ญ๐ก๐ž ๐ˆ๐ฆ๐ฉ๐š๐œ๐ญ ๐จ๐Ÿ ๐‚๐จ๐ฏ๐ข๐-๐Ÿ๐Ÿ— ๐๐š๐ง๐๐ž๐ฆ๐ข๐œ ๐จ๐ง ๐Ž๐ฌ๐ญ๐ž๐จ๐š๐ซ๐ญ๐ก๐ซ๐ข๐ญ๐ข๐ฌ ๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ๐ฌ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐†๐ฅ๐จ๐›๐š๐ฅ๐ฅ๐ฒ?

Surge in the number of COVID-19 patients and drop in the use of non-steroidal anti-inflammatory drugs and corticosteroids negatively affected the market.

As per the World Health Organization guideline published in 2019, a systemic corticosteroid can be avoided in patients who are diagnosed with osteoarthritis along with COVID-19. This has contributed to the drop in the global osteoarthritis treatment market.

The report segments the global osteoarthritis therapeutics market on the basis of drug type, anatomy, distribution channel, and region.

The knee osteoarthritis segment accounted for the largest market share in 2020, contributing to more than three-fifths of the total share, and is expected to maintain the lead throughout the forecast period. The same segment is estimated to witness the fastest CAGR of 9.3% from 2021 to 2030. The report also covers other segments such as hip osteoarthritis, hand osteoarthritis, and small joint osteoarthritis.

๐๐ซ๐จ๐œ๐ฎ๐ซ๐ž ๐‚๐จ๐ฆ๐ฉ๐ฅ๐ž๐ญ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ (๐Ÿ๐ŸŽ๐ŸŽ ๐๐š๐ ๐ž๐ฌ ๐๐ƒ๐… ๐ฐ๐ข๐ญ๐ก ๐ˆ๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ, ๐‚๐ก๐š๐ซ๐ญ๐ฌ, ๐“๐š๐›๐ฅ๐ž๐ฌ, ๐š๐ง๐ ๐…๐ข๐ ๐ฎ๐ซ๐ž๐ฌ) @

The nonsteroidal anti-inflammatory drugs segment contributed to the highest market share in 2020, contributing to nearly three-fifths of the total market share, and is anticipated to dominate the market during the forecast period. On the other hand, the visco supplementation agents segment is expected to manifest the fastest CAGR of 9.7% from 2021โ€“2030.

Europe followed by Asia-Pacific and North America, contributed to the highest share in 2020, holding nearly one-third of the total share, and is expected to maintain dominance throughout the forecast period. The Asia-Pacific region is expected to portray the fastest CAGR of 9.1% from 2021-2030.

Key players of the global osteoarthritis therapeutics market analysed in the research include Bayer AG, Pfizer Inc., Flexion Therapeutics, Inc., Abbott Laboratories, GlaxoSmithKline plc., Johnson & Johnson, Novartis, Horizon Therapeutics plc., Sanofi, and Zimmer Biomet Holding.

๐…๐จ๐ซ ๐๐ฎ๐ซ๐œ๐ก๐š๐ฌ๐ž ๐„๐ง๐ช๐ฎ๐ข๐ซ๐ฒ ๐š๐ญ:

๐Š๐ž๐ฒ ๐…๐ข๐ง๐๐ข๐ง๐ ๐ฌ ๐จ๐Ÿ ๐ญ๐ก๐ž ๐’๐ญ๐ฎ๐๐ฒ:

By anatomy, the knee osteoarthritis segment was the highest contributor to the market in 2020.

On the basis of drug type, the nonsteroidal anti-inflammatory drugs segment dominated the market in 2020, and is expected to continue this trend during the forecast period.

As per distribution channel, the hospital pharmacies segment was the highest contributor to the osteoarthritis therapeutics market in 2020.

Region-wise, Europe garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

๐“๐ซ๐ž๐ง๐๐ข๐ง๐  ๐‘๐ž๐ฉ๐จ๐ซ๐ญ๐ฌ ๐ข๐ง ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐ˆ๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ:

Gene Synthesis Market:

Mobile Tomography Market:

Plasma Fractionation Market:

Influenza Vaccine Market:

๐€๐›๐จ๐ฎ๐ญ ๐”๐ฌ:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.


David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975

David Correa
Allied Analytics LLP
email us here